Navigation Links
Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
Date:2/22/2008

nfectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug- resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com.

This press release contains "forward-looking statements" regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for Pneumocystis pneumonia (PCP). Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Immtech Announces Posting of Annual Shareholders Meeting Presentation
2. Immtech Reports Fiscal Second Quarter 2008 Results
3. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Chinese SFDA Grants Immtech Fast Track Status
7. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
8. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
9. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
10. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
11. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
(Date:9/2/2014)... 02, 2014 West Hollywood cosmetic ... consultations for Invisalign. This special offer includes a free ... to determine their candidacy for the procedure and answer ... patients may also be eligible for the Summer Invisalign ... of the month of August, patients who choose Invisalign ...
(Date:9/2/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- The quality ... overall, and dietary disparity between the rich and poor ... provides the most direct evidence to date that the ... U.S. dietary quality are having some payoff, but it ... study author Dong Wang, a doctoral student in the ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... Dallas, Texas (PRWEB) September 02, 2014 ... , “North America Resectoscopes Market Outlook to 2020? ... Resectoscopes market. The report provides value, in millions ... prices (in US dollars) within market segments –, ... Electrodes (Monopolar (Disposable and Reusable) Electrodes and Bipolar ...
(Date:9/2/2014)... USARAD Holdings Inc. a leading ... provider, including SecondOpinions.com® – consumer division is gaining ... services. The telemedicine industry pioneer is now partnering ... Founded and established in 1963 as the first ... as a maternity care hospital with very few ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... a computer based test that may reveal how easily an ... that her scientific test can be used as another ... in fields where employee distraction can lead to fatal errors. ... liable to do things like put your keys in the ...
... are hopeful that the actress' current rehab spell will bring ... wacky recent incidents . ,As the Mean Girls ... on May 28, after being arrested for DUI, her supposed ... ,One friend told America's Star magazine that Lohan ...
... of Illinois dentists provide oral cancer examinations for their ... thoroughly or at optimum intervals, according to a new ... of pre-malignant lesions and of proper examination techniques, some ... be doing to detect oral cancers in their patients," ...
... on Thursday announced that FDA has granted a standard ... Cervarix, Reuters reports. A GSK spokesperson on Thursday said ... been completed in six months. ,Cervarix and ... 100% effective in preventing infection with HPV strains 16 ...
... Dey, L.P. announced today that the U.S. Food ... Drug Application (NDA) of its marketing partner, Critical ... tablets. ZYFLO CR(TM) offers twice-daily, extended-release dosing. Under ... in March 2007, DEY will co-market Critical Therapeutics' ...
Cached Medicine News:Health News:Individuals Distraction can Be Measured by a Computer Based Test 2Health News:Dentists Need More Training in Oral Cancer Detection 2Health News:Dentists Need More Training in Oral Cancer Detection 3Health News:FDA Approves ZYFLO CR(TM) (Zileuton) for Chronic Treatment of Asthma 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: